Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02844491

Acronym

Epitopes-LNH01

Enrollment

Registered

2016-07-26

Start date

2013-01-22

Completion date

2014-09-19

Last updated

2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Malignancies B

Brief summary

Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells. CD20, a membrane antigen broadly expressed in mature B cell lymphomas, is subject to an alternative splicing named Delta-CD20 leading to loss of membrane expression of the spliced isoform. The investigators group would now determine if it's possible, in patients with lymphoproliferative B, to detect the presence of a specific memory response to delta-CD20 peptides. If this memory response exists, it will confirm the interest of this antigen as a target for tumor immunotherapy.

Interventions

OTHERadditional biological samples

blood and tissue samples

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* For all patient : •Written informed consent * For Cohort A : * Patient with hematological malignancy of high grade phenotype B (non Hodgkin's lymphoma diffuse large cell) or low grade (mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma or Waldenstrom disease), regardless the initial extension stage. * Histologically or cytologically and immunophenotypical confirmed * Patient candidate to a second-line or more therapy * First-line treatment with rituximab * For Cohort B : * Absence of prior treatment with an anti-CD20 antibody * Histologically or cytologically and immunophenotypical confirmed

Exclusion criteria

* For all patients : * Patient with any medical or psychiatric condition or disease, * Patient under guardianship, curatorship or under the protection of justice and pregnant women * For Cohort A : * Patient with chronic lymphocytic leukemia * Patient with indolent lymphoma relapsed more than 1 year after treatment with Rituximab * Patient allogeneic hematopoietic cells * Patient with linked lymphoproliferative syndrome with congenital immunosuppression (eg SCID, XLP ...) or acquired (post-transplant lymphoma)

Design outcomes

Primary

Measure	Time frame
presence of Delta-CD20 T cell responses measured by ELISPOT assay	at inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026